Genetic Testing

Genetic Testing

Global Genetic Testing Market to Reach $18.9 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Genetic Testing estimated at US$10.6 Billion in the year 2020, is projected to reach a revised size of US$18.9 Billion by 2027, growing at a CAGR of 8.6% over the analysis period 2020-2027. Prenatal & Newborn, one of the segments analyzed in the report, is projected to record a 8.8% CAGR and reach US$6.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Diagnostic segment is readjusted to a revised 8.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $4.5 Billion, While China is Forecast to Grow at 10.8% CAGR
The Genetic Testing market in the U.S. is estimated at US$4.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 10.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.2% and 8.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.Predictive & Presymptomatic Segment to Record 9.4% CAGR
In the global Predictive & Presymptomatic segment, USA, Canada, Japan, China and Europe will drive the 9.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$2.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 249 Featured) -

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • Biocartis NV
  • BioRad Laboratories
  • Cepheid Inc.
  • ELITech Group SAS
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Natera, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics AG
  • Roche Molecular Diagnostics, Inc.
  • Thermo Fisher Scientific Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Genetic Testing – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
A Prelude to Genetic Testing
Top Ten Genetic Diseases Worldwide
Different Types of Genetic Tests include
Prenatal and Newborn Screening
Diagnostic Testing
Predictive & Presymptomatic Testing
Carrier Identification
Pharmacogenomic Testing
List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
Genetic Testing Delivery Models
Genetic Sequencing Approaches
Genetic Testing Market Witnesses Sluggish Growth during COVID-19, Set to Record Exponential Growth Post-COVID
Expanding Applications to Drive Genetic Testing Market
Regional Landscape
Prenatal Testing Market to Rise
Market Outlook
2. FOCUS ON SELECT PLAYERS
Recent Market Activity
World Brands
Innovations
3. MARKET TRENDS & DRIVERS
Studies Indicate Possible Correlation between Genetic Variations Tied to Immunity and COVID-19 Severity
SEGMENT ANALYSIS
Prenatal Testing – Changing the World of Pregnancy Care
List of Available Prenatal Screening and Diagnostic Tests by Indication
Players in the Prenatal and New Born Genetic Testing Market
Conventional Invasive Pre-Natal Diagnostic Techniques – A Risky Affair
Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
Competition Intensifies in the NIPD Market
Select Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US
Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing
Predictive Diagnostics
Breast Cancer Gene Testing Market to Expand Strongly
Myriad Genetics – A Leader in Breast Cancer Testing
Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
Pharmacogenomics Development Augurs Growth of Genetic Testing Market
MARKET TRENDS AND GROWTH DRIVERS
Genetic Testing Paves the Way for Personalized Medicine
TABLE 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medic
Next-Generation Sequencing (NGS) – A Giant Leap in Genome Sequencing
Biomarker Discovery Leads to Advanced Genetic Testing
Select List of Available Tumor Markers
Immense Popularity of Ancestry Testing
Increasing Focus on Data Churning
Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases
Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing
Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment
Hybrid Labs to Bridge Gap Between Traditional and DTC Models
Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing
Emergence of Rapid DNA Testing
Oncology – A Key Focus Area for Genetic Testing
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Ageing Demographics to Drive Demand for Genetic Testing
Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 24: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 27: World 15-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 28: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 29: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 30: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 31: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 33: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
Use of Genomic Data in Clinical Settings to Gather Pace
The United States: Leading Market for Genetic Testing Globally
Predictive Screening: Another Growth Area
Growing Relevance of Personalized Medicine Augurs Well
Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing
Estimated Number of New Cancer Cases and Deaths in the US (2019)
Newborn Testing Gains Ground
Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing
Coverage of NIPT in Average Risk Pregnancies Expands Target Market
Direct-to-Consumer Testing: A Growing Market
Favorable Reimbursement Policies
Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
Demographic Changes Offer Growth Opportunities
TABLE 14: North American Aging Population by Age Group: 1975-2050
Skepticism Limits Widespread Adoption of Genetic Testing
Competitive Overview
Myriad Eyes Diversification and Expansion for Growth
Natera Holds Fort in the NIPT Market
Invitae Banks on Low Cost Solutions for Expanding Revenues
Regulatory Environment
Genetic Information Nondiscrimination Act Boosts Genetic Testing
Stricter Regulations for DTC Genetic Testing
FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests
Select Genetic Test Reimbursement Codes
Market Analytics
TABLE 34: USA Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 35: USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 36: USA 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 37: USA Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 38: USA Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 39: USA 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
CANADA
Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
Number of New Cancer Cases in Canada: 2019
Regulatory Scenario
Market Analytics
TABLE 40: Canada Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 41: Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 42: Canada 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 43: Canada Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 44: Canada Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 45: Canada 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
JAPAN
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Demographics Drive Market Growth
DTC Genetic Testing Regulatory Scenario
TABLE 46: Japan Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 47: Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 48: Japan 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 49: Japan Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 50: Japan Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 51: Japan 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
CHINA
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Market Overview
China Attracts Domestic and Foreign Players
Strong Focus on Genomics
Genetic Testing to Reveal Real Talent in Children – A New Popular Application
China to Take Lead in Rapidly Growing Asian Genomics Market
Market Analytics
TABLE 52: China Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 53: China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 54: China 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 55: China Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 56: China Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 57: China 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
EUROPE
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
European Personalized Medicine Market to Exhibit Robust Growth
Aging Population to Drive Demand for Genetic Testing
TABLE 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above
Legislations/Regulatory Policies in Select European Countries
Legislations Governing Genetic Testing in Select European Countries
Rising Cancer Incidence Augurs Well for European Genetic Testing Market
Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
TABLE 58: Europe Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 59: Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 60: Europe 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 61: Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 62: Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 63: Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 64: Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 65: Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 66: Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
FRANCE
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 67: France Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 68: France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 69: France 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 70: France Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 71: France Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 72: France 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
GERMANY
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Parliamentary Regulations
TABLE 73: Germany Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 74: Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 75: Germany 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 76: Germany Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 77: Germany Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 78: Germany 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
ITALY
TABLE 79: Italy Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 80: Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 81: Italy 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 82: Italy Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 83: Italy Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 84: Italy 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
UNITED KINGDOM
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
Increased Support for Personalized Medicine to Drive Genetic Testing
SMIP for Pharmacogenomic Testing
Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
Principles for DTC Genetic Testing Laid out by HGC
TABLE 85: UK Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 86: UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 87: UK 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 88: UK Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 89: UK Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 90: UK 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 91: Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 92: Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 93: Rest of Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 95: Rest of Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 96: Rest of Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Healthcare Spending in Asia-Pacific: On the Rise
India
Australia and New Zealand
Market Analytics
TABLE 97: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 98: Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 99: Asia-Pacific 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 101: Asia-Pacific Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 102: Asia-Pacific 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
REST OF WORLD
Predictive Screening: Another Growth Area
Market Analytics
TABLE 103: Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 104: Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 105: Rest of World 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2021 & 2027
TABLE 106: Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 107: Rest of World Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 108: Rest of World 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 249

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings